{
  "abstract": "Introduction: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterised by abdominal pain and altered bowel habits and is associated with reduced quality of life. Although several treatments are effective at the group level, treatment responses vary substantially between individuals, highlighting the need for personalised approaches. This trial investigates moderators and mediators of treatment response to two established IBS interventions to determine for whom treatments are most effective and how they exert their effects.\n\nMethods and analysis: This parallel-group randomised controlled trial will enrol 235 adults with IBS from community, primary and tertiary care across Australia and the US. Participants will be randomised to a 12 week online fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet intervention targeting reduction of fermentable carbohydrate intake or an exposure-based cognitive behavioural therapy (E-CBT) programme targeting symptom-related avoidance behaviours, each with therapist support (dietitian or psychologist, respectively). The primary objective is to assess moderators and mediators of treatment response on gastrointestinal symptom severity, measured using the Gastrointestinal Symptom Rating Scale (GSRS-IBS), assessed weekly from baseline to week 12. Pre-specified moderators and mediators include gastrointestinal-specific anxiety and avoidance behaviour and total FODMAP intake; treatment preference will also be examined as a moderator. Treatment expectancy and credibility and therapeutic alliance will be assessed as covariates accounting for non-specific treatment effects. Secondary outcomes, assessed at baseline, post-treatment (12 weeks) and 3- and 6-month post-intervention follow-up, include IBS-specific symptom severity (measured using the IBS-Symptom Severity Scale, IBS-SSS), IBS-related quality of life, eating-related symptoms, psychological symptoms, extraintestinal symptom distress, stool frequency and consistency and gut microbiome composition and function. We will also assess gastrointestinal symptom severity by the GSRS-IBS at 3- and 6-month follow-up to assess maintenance. Linear mixed-effects models will assess treatment effects and moderation. Latent growth curve modelling and time-lagged mixed-effects models will examine mediation.\n\nEthics and dissemination: Ethical approval was obtained from the University of Melbourne Human Research Ethics Committee (Project ID: 31186). This manuscript is based on protocol V.4.0 (06–04-26). Recruitment is ongoing. Results will be disseminated via peer-reviewed publications and presentations at scientific meetings.\n\nTrial registration number: NCT06940596.",
  "abstract_shown": true,
  "affiliations": [
    "Human Nutrition Group, Faculty of Science, The University of Melbourne, Melbourne, Victoria, Australia",
    "Department of Clinical Neuroscience, Division of Psychology, Karolinska Institute, Stockholm, Sweden",
    "Harvard Medical School, Boston, Massachusetts, USA",
    "Center for Neurointestinal Health, Massachusetts General Hospital, Boston, Massachusetts, USA",
    "Department of Gastroenterology, Alfred Health, Monash University, Melbourne, Victoria, Australia",
    "Department of Gastroenterology, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia",
    "Department of Medicine, The University of Melbourne, St Vincent’s Hospital, Melbourne, Victoria, Australia",
    "Laboratory for Brain-Gut Axis Studies (LaBGAS),Translational Research Centre for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases & Metabolism (CHROMETA), KU Leuven, Leuven, Belgium"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jacqueline L Anderson",
      "orcid": "0000-0002-6704-6543"
    },
    {
      "affs": [
        1
      ],
      "name": "Brjánn Ljótsson"
    },
    {
      "affs": [
        2,
        3
      ],
      "name": "Helen Burton-Murray"
    },
    {
      "affs": [
        0
      ],
      "name": "Madeline L West"
    },
    {
      "affs": [
        4,
        5
      ],
      "name": "Chu K Yao"
    },
    {
      "affs": [
        6
      ],
      "name": "Chamara Basnayake"
    },
    {
      "affs": [
        7
      ],
      "name": "Lukas Van Oudenhove"
    },
    {
      "affs": [
        0
      ],
      "name": "Jessica R Biesiekierski",
      "orcid": "0000-0002-6175-6325"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/da0sy5x9aje1k.bib",
  "cited_by": 0,
  "doi": "10.1136/bmjopen-2026-126664",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13756487/",
  "id": "da0sy5x9aje1k",
  "issns": [
    "2044-6055",
    "2044-6055"
  ],
  "landing_url": "https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-126664",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "1506"
    ],
    [
      "heading",
      "1695"
    ],
    [
      "heading",
      "Gastroenterology and Hepatology"
    ],
    [
      "heading",
      "Protocol"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": "PMC13756487",
  "pmid": "43015024",
  "published": "2026-11-11",
  "publisher": "BMJ",
  "ris": "https://research.draconitic.com/paper/da0sy5x9aje1k.ris",
  "sources": [
    {
      "first_seen": "2026-11-12T00:20:53Z",
      "native_id": "10.1136/bmjopen-2026-126664",
      "source": "crossref",
      "url": "https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-126664"
    },
    {
      "first_seen": "2026-11-16T12:22:21Z",
      "native_id": "PMC13756487",
      "source": "pmc",
      "url": "https://doi.org/10.1136/bmjopen-2026-126664"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:F27",
      "subfield": "general"
    }
  ],
  "title": "Exclude or expose in irritable bowel syndrome study: what works for whom and how? Protocol for a randomised controlled trial of internet-delivered FODMAP diet versus exposure-based cognitive behavioural therapy",
  "title_text": "Exclude or expose in irritable bowel syndrome study: what works for whom and how? Protocol for a randomised controlled trial of internet-delivered FODMAP diet versus exposure-based cognitive behavioural therapy",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:22:21Z",
  "url": "https://research.draconitic.com/paper/da0sy5x9aje1k",
  "venue": "BMJ Open",
  "versions": []
}